Taiwan Liposome Company (TLC)

69 articles about Taiwan Liposome Company (TLC)

• 

  Mereo BioPharma's Rationale for Halting IPO Draws Skepticism

  4/27/2018

  Mereo pulled its planned initial public offering (IPO) on the Nasdaq Global Market, saying market conditions were not in the best interests of its shareholders. The company’s statement is getting some pushback from investors and analysts.

• TLC and Jixi Biotechnology Partners Announce Joint Venture

  1/23/2018

  The new partnership’s efforts will take place pursuant to recent reforms by the CFDA, which include initiatives designed to accelerate drug approvals and encourage innovation, including greater alignment of China's review process with that of the US and the EU.

• Taiwan Liposome Company (TLC) President Unveils Growth and Hiring Plans

  1/25/2017

• Taiwan Liposome Company (TLC) Release: TLC178 Granted Orphan Drug Designation By U.S. FDA For The Treatment Of Cutaneous T-cell Lymphoma (CTCL)

  10/19/2016

• Taiwan's Taiwan Liposome Company (TLC) Approved To Begin U.S. Clinical Trials Of Cancer Drug

  10/4/2016

• SciClone Pharmaceuticals, Inc. and Taiwan Liposome Company Enter Into a Licensing Agreement for ProFlow®, a Novel Treatment for Peripheral Arterial Disease for the China Market

  6/25/2013

• Taiwan Liposome Company's Liver Cancer Drug Put on Fast Track in China

  3/19/2013

• Aptuit Consulting, Inc. and Taiwan Liposome Company Collaborate to Complete all IND Enabling Work and IND Submission for Novel Anti-Cancer Treatment in 12 Months

  6/25/2008

• SRI International To Conduct Preclinical Studies Of Cancer Drug For Taiwan Liposome Company

  10/3/2006